Novo Nordisk's new CEO, Maziar Mike Doustdar, faces challenges in reviving waning sales and shares in the weight-loss drug ...

Speaking from Astra's offices in New York, Sir Pascal Soriot (pictured) said it was 'global', but it was 'very much rooted ...

Merck is a strong and profitable pick meeting Benjamin Graham's criteria. Read more on why investors need to stay aware of ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

While value has outperformed growth in Europe over the past five years, Europe now represents less than half of equity market ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D) ...

The announcement by AstroZeneca follows a growing trend of companies pledging to invest in pharmaceutical manufacturing on ...

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar ...